Note: Where available, the PDF/Word icon below is provided to view the complete and fully formatted document
Labor welcomes good news for children with cystic fibrosis



Download PDFDownload PDF

CATHERINE KING MP

SHADOW MINISTER FOR HEALTH AND MEDICARE

MEMBER FOR BALLARAT

LABOR WELCOMES GOOD NEWS FOR CHILDREN WITH CYSTIC FIBROSIS

The confirmation that the drug Kalydeco will be listed on the Pharmaceutical Benefits Schedule is welcome news for young children with cystic fibrosis and their families.

The drug has been labelled a "game changer" in alleviating the devastating symptoms for children aged 2-5 with cystic fibrosis, a critical time in their development.

Earlier this year, Labor wrote to the Government offering our bipartisan support and urging them to work with the manufacturer to resolve the issues stopping Kalydeco from being listed on the PBS - as the independent Pharmaceutical Benefits Advisory Committee had also suggested. We are pleased that this happened.

Labor created the Pharmaceutical Benefits Scheme to ensure Australians have affordable access to a wide range of medicines, and we are incredibly proud of the ongoing impact of the scheme today.

Labor knows how much today's news means to families of young children with cystic fibrosis right around the country - we are delighted that they will have access to subsidised Kalydeco.

TUESDAY, 7 FEBRUARY 2017

MEDIA CONTACT: JOANNE CLEARY 0428 816 751